William Blair Has Positive Outlook of TERN FY2025 Earnings

Key Points

• William Blair has revised its FY2025 earnings estimate for Terns Pharmaceuticals to a loss of ($1.09) per share, up from a previous forecast of ($1.10).
• In the latest quarterly earnings report, Terns Pharmaceuticals reported a loss of ($0.26) per share, exceeding consensus estimates of ($0.28) by $0.02.
• Insider transactions indicate confidence in the company's future, with CEO Amy L. Burroughs and CFO Andrew Gengos significantly increasing their stock holdings in recent months.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Analysts at William Blair lifted their FY2025 earnings per share (EPS) estimates for Terns Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($1.09) per share for the year, up from their previous forecast of ($1.10). The consensus estimate for Terns Pharmaceuticals' current full-year earnings is ($1.19) per share. William Blair also issued estimates for Terns Pharmaceuticals' Q1 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.20) EPS and FY2027 earnings at ($1.41) EPS.

Other analysts have also issued research reports about the company. JMP Securities reiterated a "market outperform" rating and set a $20.00 price objective on shares of Terns Pharmaceuticals in a report on Monday, April 21st. BMO Capital Markets decreased their price target on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Terns Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $15.63.

Terns Pharmaceuticals Stock Performance

TERN traded up $0.19 during trading on Friday, hitting $6.49. The stock had a trading volume of 1,057,982 shares, compared to its average volume of 1,160,280. The stock has a 50 day simple moving average of $4.75 and a two-hundred day simple moving average of $3.80. Terns Pharmaceuticals has a twelve month low of $1.87 and a twelve month high of $11.40. The company has a market capitalization of $567.50 million, a PE ratio of -6.25 and a beta of -0.05.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, CFO Andrew Gengos purchased 10,000 shares of the stock in a transaction on Friday, June 27th. The stock was bought at an average price of $3.93 per share, with a total value of $39,300.00. Following the transaction, the chief financial officer owned 25,000 shares in the company, valued at $98,250. The trade was a 66.67% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amy L. Burroughs acquired 23,314 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was purchased at an average cost of $3.87 per share, for a total transaction of $90,225.18. Following the completion of the acquisition, the chief executive officer directly owned 47,083 shares of the company's stock, valued at approximately $182,211.21. This trade represents a 98.09% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 48,314 shares of company stock worth $186,575. 1.50% of the stock is owned by insiders.

Institutional Trading of Terns Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. increased its stake in shares of Terns Pharmaceuticals by 33.4% in the fourth quarter. American Century Companies Inc. now owns 113,225 shares of the company's stock worth $627,000 after acquiring an additional 28,330 shares during the period. LPL Financial LLC boosted its holdings in Terns Pharmaceuticals by 397.2% in the fourth quarter. LPL Financial LLC now owns 252,325 shares of the company's stock valued at $1,398,000 after purchasing an additional 201,575 shares during the last quarter. Vanguard Group Inc. grew its position in Terns Pharmaceuticals by 15.3% during the 4th quarter. Vanguard Group Inc. now owns 3,869,582 shares of the company's stock worth $21,437,000 after purchasing an additional 512,768 shares during the period. Corebridge Financial Inc. raised its stake in shares of Terns Pharmaceuticals by 13.5% during the 4th quarter. Corebridge Financial Inc. now owns 34,951 shares of the company's stock valued at $194,000 after buying an additional 4,169 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Terns Pharmaceuticals in the 4th quarter valued at about $4,706,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.